gemilukast
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01297582)
Timeline
Indications
Studied for
Mechanism of action
- Cysteinyl leukotriene receptor 2ANTAGONIST
CYSLTR2 antagonist
- Cysteinyl leukotriene receptor 1ANTAGONIST
CYSLTR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(F)cccc1CCCCOc1ccc(C#Cc2ccc(F)c3c(CCCC(=O)O)c(C)n(CCCC(=O)O)c23)cc1- Mol. weight
- 601.69 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3597634 ↗
Also known as
- 4,4'-(4-fluoro-7-(2-(4-(4-(3-fluoro-2-methylphenyl)butoxy)phenyl)ethynyl)-2-methyl-1h-indole-1,3-diyl)dibutanoic acid
- gemilukast
- ono-6950
- ono-6950
- ono-6950
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01551147 | Phase 2 | Jun 1, 2012 | Ono Pharmaceuticals |
| NCT01536041 | Phase 2 | Mar 1, 2012 | Ono Pharmaceuticals |
| NCT01405651 | Phase 1 | Jul 1, 2011 | Ono Pharmaceuticals |
| NCT01297582 | Phase 1 | Jan 1, 2011 | Ono Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ono Pharmaceuticals | For profit | 4 | 4 | 2 | 2011 |
1 organizations
Page 1 / 1